학술논문
Response to Steele and Acheson.
Document Type
Article
Source
Subject
*MEDICAL personnel
*PAIN clinics
*PHARMACEUTICAL policy
*
*
Language
ISSN
0959-5236
Abstract
Steele and Acheson's [1] commentary touches on a number of significant issues confronting opioid agonist treatment (OAT) in Australia. Transfer of clients to community pharmacies for dosing was also an important strategy to reduce the congregation of large numbers of clients in public clinics for both client and staff safety. Unsupervised treatment (up to 4 weeks supply of take-away doses) with SL buprenorphine has been possible across Australia for over a decade [4], yet until recently, only a very small proportion of clients were prescribed monthly, fortnightly or weekly take away doses. [Extracted from the article]